Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

December 7, 2017 2017 Review: PARP Inhibitor Update and Approvals As the holiday season approaches, CrownBio is celebrating with a look back over the important research and scientific stories from 2017. Our Blog team are reviewing the top trends and news that were important to each of them over the last year. LEARN MORE
December 1, 2017 Mouse Clinical Trials - The Power Behind Study Design: Top 10 Questions Mouse Clinical Trials (MCT) using patient-derived xenograft (PDX) models are a key preclinical tool for predicting drug ... LEARN MORE
November 28, 2017 How Gut Bacteria Influence Cancer Treatment Efficacy Over the past few years, scientists have come to a deeper understanding of how microorganisms can be seen as a major ... LEARN MORE
November 20, 2017 Misidentified Cell Lines: The Scale of the Problem and How to Avoid It Cell lines have been the cornerstone of life science research for decades. Yet they’ve been misidentified and misused ... LEARN MORE
November 10, 2017 EORTC 2017 Short Talk Review Transcriptomic Analysis of Patient-Derived Xenografts Reveals Heterogeneity in Human and Mouse Stroma/Immune ... LEARN MORE
November 8, 2017 Humanized Mouse Clinical Trials for Immunotherapy Development Recent posts have covered the different types of mouse clinical trial (MCT) and which is most suited to any given drug ... LEARN MORE
November 3, 2017 Using PDX as Surrogate Models for TME Investigation The diversity of cancers is due to the fact that there are numerous different types, along with many different mutations. In previous blogs we have discussed how both heterogeneity and the tumor microenvironment (TME) play a role in tumor progression, metastasis, and resistance, as well as how stromal interactions and the immune microenvironment are ... LEARN MORE
October 31, 2017 How to Choose the Right Type of Mouse Clinical Trial As covered in our recent blog post, Mouse Clinical Trials using patient-derived xenograft (PDX) models provide more ... LEARN MORE
October 26, 2017 Post FDA Approval: CAR-T Therapy Key Facts A few weeks ago, the FDA issued a historic approval of the first cancer cell therapy using a chimeric antigen receptor ... LEARN MORE
October 24, 2017 Top 5 Reasons To Use Mouse Clinical Trials Preclinical oncology drug development needs new tools and approaches. Current methods result in 95% attrition rates for ... LEARN MORE
October 19, 2017 Quick Guide: Top 3 AML Approval Trends for 2017 Acute myeloid leukemia has been the focus of much drug development, but few drug approvals, for the past few decades. While there have been significant research efforts into characterizing AML, and improving patient outcomes, the standard therapy for most subtypes of newly diagnosed AML has remained unchanged for the last 40 years. LEARN MORE
October 17, 2017 The Role of Gut Microbiota and Implications for IBD Over the past 10 years, scientists have discovered that changes in the composition of the gut microbiota play a pivotal ... LEARN MORE
October 12, 2017 Organ-on-a-Chip: The Future of Improved Drug Discovery? I’m a firm believer in the use of animal models in medical research. This is so for many reasons. A chemist and mentor ... LEARN MORE
October 10, 2017 ADA 2017 Video Poster Review Naturally Diabetic NHP Immune Cell Changes Correspond to Human Type 2 Diabetes While changes in immune cell ... LEARN MORE
October 5, 2017 What's Next for Immune Checkpoint Inhibitors: TIM-3? Unlike negative regulators, such as PD-1 and CTLA-4 (which have been proposed as therapeutic targets in different ... LEARN MORE